What Vivostat does

Vivostat A/S is a Denmark-based, privately held medical device company (founded 1992, headquartered in Allerød) that develops, manufactures and distributes the Vivostat System — the first and only platform for on-site preparation and application of fully autologous (patient-derived) fibrin sealant and platelet-rich fibrin matrix. The system consists of a Processor Unit (PRO 800), Applicator Units (APL 400/404), and procedure-optimized single-use disposable sets. Its product portfolio spans Vivostat Fibrin (haemostasis/tissue sealing, launched 2001), Vivostat PRF (tissue regeneration, 2005), Obsidian ASG (anastomotic reinforcement in GI surgery, 2021), Obsidian RFT (regenerative treatment of complex fistulas, 2021), and ArthroZheal (arthroscopic orthopaedic surgery, 2022). The Co-Delivery platform (APL 404) enables simultaneous on-site application of BMAC, stem cells, chondrocytes, or antibiotics alongside the base biological product.

The company sells predominantly through a curated distributor network spanning 40+ countries across Europe, Africa, Asia and South America, supplemented by participation in major European surgical congresses (EACTS, ESCP, ESTS, ESSKA, EAES, ESA, Eurospine) and hands-on LIVE workshops hosted at leading surgical centers (Ghent, Linz, Athens, Sofia, Novi Sad, Pamplona, Vienna). Go-to-market is channel- and event-driven rather than direct sales. Revenue mechanics combine hardware placement (processor/applicator units) with recurring single-use disposable consumables per procedure, creating a razor-and-blade model, although public pricing is not disclosed. The company is small (11-50 employees, with most production and specialist functions outsourced to consultants) and has historically been funded by EU grants (SME Instrument Phase 1, 2019-2020; Horizon 2020 EIC Accelerator, 2021-2024) supporting a pivotal Phase III trial of Obsidian ASG across a minimum of 12 EU clinics and 250 patients. In December 2025, Vivostat International GmbH acquired 100% of Vivostat A/S; the operating company continues independently under the same management team.

Name

Vivostat

Legal name

Vivostat A/S

Website

https://vivostat.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Surgical medical devices — autologous biologics for haemostasis and tissue regeneration

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Adhesives & Sealants (2891)

akta.pro primary industry

Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin) (HLAIAHAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Autologous fibrin sealant
• Platelet rich fibrin matrix
• Surgical tissue sealing
• Orthobiologic surgical devices
• On-site blood processing system

Headquarters

HQ city

Allerød

HQ country

Denmark

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Sale of the Vivostat System including Processor Unit (PRO 800), Applicator Units (APL 400/APL 404), and disposable sets for preparation and application. Single-use disposable sets are optimized for different surgical procedures.
2. Disposable Products: Single-use disposable sets required for preparation and application, each optimised for different surgical procedures. These create recurring revenue through repeat purchases.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Vivostat A/S develops, manufactures and distributes the Vivostat System — a proprietary medical device platform (Processor Unit PRO 800 + Applicator Unit APL 400/APL 404 + procedure-optimized single-use Disposable Sets) that automates on-site preparation of autologous (patient-derived) concentrated fibrin sealant and platelet-rich fibrin (PRF) matrix from a patient's own blood. Its biological product portfolio built on this platform includes Vivostat Fibrin (autologous fibrin sealant), Vivostat PRF (autologous platelet-rich fibrin matrix with embedded growth factors), ArthroZheal (PRF for arthroscopic orthopaedic surgery), Obsidian ASG (platelet-rich bioactive matrix for anastomotic reinforcement after GI resection), and Obsidian RFT (sphincter-sparing regenerative fistula treatment). All offerings target surgical haemostasis, tissue sealing and tissue regeneration across multiple surgical specialties and are sold to hospitals and surgical centers through European and selected emerging-market distributors.

Product overview

Vivostat offers a portfolio of medical devices and autologous biological products centered on the Vivostat System—a hardware-based platform for preparing and applying patient-derived fibrin sealants and platelet-rich fibrin matrices. The core products include Vivostat Fibrin (autologous fibrin sealant) and Vivostat PRF (autologous platelet-rich fibrin matrix), both prepared on-site from the patient's own blood using the proprietary Processor Unit PRO 800 and Applicator Unit APL 400/APL 404. Specialty applications are addressed through ArthroZheal (for orthopaedic/arthroscopic surgery) and the Obsidian product line (ASG for anastomotic reinforcement in GI surgery, RFT for regenerative fistula treatment). The Vivostat Co-Delivery system enables simultaneous application of stem cells, BMAC, chondrocytes, or antibiotics alongside the base products. The company also distributes Nexon Medical's EnSight Biportal Endoscopy system for spinal surgery in Scandinavia. All Vivostat products are designed to support haemostasis, tissue sealing, and tissue regeneration across multiple surgical specialties.

Differentiator

Problem solved

Functional benefit

Brands

• Vivostat System: The first and only system for on-site preparation and application of autologous concentrated fibrin sealant and platelet rich fibrin matrix.
• Vivostat Fibrin
• Vivostat PRF
• Vivostat Co-Delivery
• Obsidian ASG (Anastomoses SafeGuard)
• Obsidian RFT (Regenerative Fistula Treatment)
• ArthroZheal

Products and services

• Vivostat System First and only system for on-site preparation and application of autologous concentrated fibrin sealant and platelet rich fibrin matrix. Consists of Processor Unit (PRO 800), Applicator Unit (APL 400 / APL 404) and procedure-optimized single-use Disposable Sets. Targeted at surgical departments across cardiac, GI, colorectal, thoracic, orthopaedic, neurosurgery, vascular, urology, maxillofacial/ENT and wound care settings.
• Vivostat Fibrin Autologous fibrin sealant prepared on-site from the patient's own blood using the Vivostat System. Provides haemostasis and tissue sealing with high elasticity and polymerization properties for surgical use.
• Vivostat PRF (Platelet Rich Fibrin) Autologous platelet-rich fibrin matrix containing multiple growth factors embedded in a matrix. Provides haemostasis, tissue sealing and tissue regeneration across surgical procedures including burn, cardiac and neurosurgery.
• ArthroZheal Platelet rich fibrin matrix specifically designed for arthroscopic surgery, providing bioactive and biocompatible properties for sealing, healing and regeneration of ligaments, tendons and cartilage. Targets orthopaedic/arthroscopic surgeons.
• Obsidian ASG (Anastomoses SafeGuard) Autologous platelet-rich bioactive matrix for anastomotic reinforcement and protection following resection surgery in the gastrointestinal tract. Supports tissue sealing, mechanical protection and angiogenic healing to reduce the risk of anastomotic leakage. Targets GI / colorectal surgeons.
• Obsidian RFT (Regenerative Fistula Treatment) Autologous platelet-rich bioactive matrix for regenerative treatment of fistulas. Provides a sphincter-sparing minimally invasive procedure that can close and heal fistulas with optional antibiotic co-delivery. Targets colorectal surgeons / coloproctologists.
• Vivostat Co-Delivery Revolutionary co-application system enabling simultaneous delivery of BMAC, stem cells, chondrocytes or medications (e.g. antibiotics) together with Vivostat fibrin or PRF product directly at the surgical site.
• EnSight Biportal Endoscopy System (distribution) Unilateral Biportal Endoscopy (UBE) system for spinal surgery, manufactured by Nexon Medical International and distributed by Vivostat in Denmark and Sweden as an extension of Vivostat's medical device portfolio.

Quantifiable outcome

• Obsidian ASG reduced leakage rate by more than 50% in gastrointestinal resections (pre-clinical studies)
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Nexon Medical InternationalcoreChannel Partner/ Reseller/ Distributor · 9 January 2025Vivostat became a distributor of Nexon Medical International's EnSight Biportal Endoscopy system for spinal surgery. Set and ready to deliver the system to surgeons in Denmark and Sweden. This partnership widens Vivostat's scope to deliver high quality medical devices in general to the Nordic countries beyond their own Vivostat System products.
• RivolutioncoreStrategic or Co-development Partner · 1 May 2021Vivostat and Rivolution worked together for more than 4 years to develop a new product focused on reducing anastomotic leakage in gastrointestinal surgery. This collaboration led to the development of Obsidian ASG, which combines a new intra-anastomotic application technique with the advantage of a product that both seals and provides growth factors to accelerate the healing process.
• Duomed GroupminorGTM or Marketing PartnerDuomed Group supported the Obsidian RFT LIVE workshop hosted by Ghent University Hospital in Belgium.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Baxter International: Baxter manufactures Tisseel and other fibrin sealants used in the same surgical specialties (cardiothoracic, general surgery, orthopedics) that Vivostat targets. As a large, publicly-traded medical device incumbent, Baxter is the primary established player competing against Vivostat's autologous fibrin sealant offering.
• Ethicon (Johnson & Johnson MedTech): Ethicon markets Evicel fibrin sealant and a broad portfolio of surgical hemostats and sealants used in the same open and minimally invasive procedures Vivostat addresses. Direct overlap in fibrin sealant category combined with significantly larger scale make this a key incumbent competitor.
• CSL Behring: CSL Behring is a major plasma-derived therapies manufacturer with fibrin sealants and other plasma protein products used in surgical hemostasis. Comparable biological-product manufacturing footprint and surgical end markets make it a broad incumbent peer for Vivostat's fibrin sealant line.
• Grifols: Grifols is one of the world's largest plasma fractionators producing plasma-derived hemostats and surgical sealants. As a broad incumbent in plasma-derived surgical biologics, Grifols is comparable to Vivostat from a category standpoint, though Vivostat differentiates on autologous (rather than donor-derived) sourcing.
• Octapharma: Octapharma manufactures plasma-derived products including fibrin sealants marketed across Europe. Overlapping therapeutic positioning in surgical hemostasis with fibrin-based products makes Octapharma a broad incumbent comparable to Vivostat's fibrin sealant offering.
• Takeda Pharmaceutical Company: Takeda, through its Plasma-Derived Therapies business (formerly Shire/Baxalta), manufactures fibrin sealants and other plasma-derived surgical products. Comparable from a category-and-clinical-use standpoint for surgical hemostasis, though at a much larger portfolio scale.
• Stryker (Orthobiologics): Stryker's orthobiologics portfolio includes platelet-rich plasma (PRP) systems and tissue-repair matrices used in arthroscopic and orthopedic surgery, directly comparable to Vivostat's ArthroZheal product. As a broad medical device incumbent, Stryker is a key competitor in the orthobiologics space Vivostat targets.

Direct peers

• Artivion (formerly CryoLife): Artivion (formerly CryoLife) sells BioGlue surgical adhesive and other tissue-preservation products used in cardiac and vascular surgery, directly competing with Vivostat's hemostasis and tissue sealing applications. Closely comparable product category, surgical use cases, and customer base make this a direct peer.
• TETEC AG: TETEC AG develops autologous and tissue-engineered cartilage products for orthopaedic applications, closely comparable to Vivostat's ArthroZheal matrix used in arthroscopic surgery for cartilage, tendon, and ligament repair. Both companies operate in regenerative orthobiologics with surgeon-channel distribution.

Emerging players

• Geistlich Pharma: Geistlich Pharma markets regenerative matrices and biomaterials for dental, orthopedic, and wound healing applications. Comparable in collagen- and tissue-based regenerative medicine used in surgery, with overlapping end-user specialties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@Vivostat
• LinkedInlinkedin.com/company/vivostat-a-s

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivostat